Related Experiment Video
Updated: Jun 29, 2025
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
In vivo manufacture and manipulation of CAR-T cells for better druggability
Rui Hou1, Xiaoxue Zhang2, Xu Wang3,4,5
1College of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Abstract:
The current CAR-T cell therapy products have been hampered in their druggability due to the personalized preparation required, unclear pharmacokinetic characteristics, and unpredictable adverse reactions. Enabling standardized manufacturing and having clear efficacy and pharmacokinetic characteristics are prerequisites for ensuring the effective practicality of CAR-T cell therapy drugs. This review provides a broad overview of the different approaches for controlling behaviors of CAR-T cells in vivo. The utilization of genetically modified vectors enables in vivo production of CAR-T cells, thereby abbreviating or skipping the lengthy in vitro expansion process. By equipping CAR-T cells with intricately designed control elements, using molecule switches or small-molecule inhibitors, the control of CAR-T cell activity can be achieved. Moreover, the on-off control of CAR-T cell activity would yield potential gains in phenotypic remodeling. These methods provide beneficial references for the future development of safe, controllable, convenient, and suitable for standardized production of CAR-T cell therapy products.
Insights
New strategies enhance Chimeric Antigen Receptor T-cell (CAR-T) therapy by enabling in vivo production and precise control of CAR-T cells, improving safety and manufacturing for broader clinical application.
Area of Science:
- Immunology
- Biotechnology
- Cell Therapy
Background:
- Current CAR-T cell therapies face challenges in druggability due to complex manufacturing, undefined pharmacokinetics, and unpredictable side effects.
- Standardized production and clear efficacy/pharmacokinetic profiles are crucial for practical CAR-T cell drug development.
Purpose of the Study:
- To review diverse strategies for controlling CAR-T cell behavior in vivo.
- To highlight methods that improve safety, controllability, and manufacturability of CAR-T cell therapies.
Main Methods:
- Genetically modified vectors for in vivo CAR-T cell generation, bypassing extensive in vitro expansion.
- Incorporation of molecular switches and small-molecule inhibitors for tunable CAR-T cell activity.
- Exploration of on-off control mechanisms for CAR-T cell activity and phenotypic remodeling.
Main Results:
- In vivo CAR-T cell production offers a streamlined alternative to traditional in vitro methods.
- Engineered control elements allow for precise modulation of CAR-T cell function and activity.
- Controlled CAR-T cell activity can influence phenotypic remodeling, potentially enhancing therapeutic outcomes.
Conclusions:
- Novel approaches facilitate the development of safer, more controllable, and conveniently manufactured CAR-T cell therapies.
- These advancements pave the way for standardized CAR-T cell production, increasing accessibility and practicality.
- The reviewed methods offer valuable insights for future CAR-T cell therapy product development.
